Compare ARGX & TTWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARGX | TTWO |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0B | 39.1B |
| IPO Year | 2017 | 1999 |
| Metric | ARGX | TTWO |
|---|---|---|
| Price | $705.83 | $207.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 16 |
| Target Price | ★ $991.56 | $283.81 |
| AVG Volume (30 Days) | 306.1K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,633,600,000.00 |
| Revenue This Year | $40.84 | $20.49 |
| Revenue Next Year | $22.38 | $36.48 |
| P/E Ratio | $33.69 | ★ N/A |
| Revenue Growth | N/A | ★ 5.31 |
| 52 Week Low | $510.06 | $188.56 |
| 52 Week High | $934.62 | $264.79 |
| Indicator | ARGX | TTWO |
|---|---|---|
| Relative Strength Index (RSI) | 29.07 | 44.05 |
| Support Level | $698.92 | $188.65 |
| Resistance Level | $856.67 | $260.95 |
| Average True Range (ATR) | 18.15 | 6.09 |
| MACD | -4.87 | 0.66 |
| Stochastic Oscillator | 11.39 | 16.76 |
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three-fourths of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.